2022 San Antonio Breast Cancer Symposium See Presentations of Interest 
Oncotype DX Breast Recurrence Score

Clinical evidence for the Oncotype DX® test in node-positive patients

The Recurrence Score® result has been proven to be predictive of chemotherapy benefit for HR+, HER2-, node-positive postmenopausal patients in the retrospective SWOG-8814 study1. The prospective randomized trial RxPONDER including more than 5 000 patients was designed to refine chemotherapy benefit estimates for HR+, HER2- patients with Recurrence Score results 0-25 with 1 to 3 positive nodes3. Initial results of the RxPONDER study have been described as practice-changing.2

  • Postmenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 can forgo adjuvant chemotherapy regardless of the number of affected nodes, tumour grade and size3
  • Premenopausal women with 1 to 3 positive nodes and Recurrence Score results 0-25 have a 2.9% benefit from chemotherapy based on distant recurrence at 5 years3

Clinical Evidence


The Oncotype DX Breast Recurrence Score test identifies the majority of node-positive women who will not benefit from and can safely be spared chemotherapy.1

  • Oncotype DX is the only multigene assay proven to predict chemotherapy benefit regardless of nodal status.1,4-5 Find out more about the difference between prognostic and predictive
  • The Oncotype DX test has been studied in more than 96,000 breast cancer patients in over 79 registry and clinical trials.1-2,4-9,11-12
  • There is a consistent and large body of evidence across randomized, prospective and retrospective studies and real-world evidence.1-2,4-9,11-12
  • The Oncotype DX Breast Recurrence Score test has been incorporated into major clinical practice guidelines worldwide.13-18

Contact Us